Erythropoietin (EPO) Market Report 2026

Erythropoietin (EPO) Market Overview

• Erythropoietin (EPO) market size has reached to $19.25 billion in 2025 • Expected to grow to $35.04 billion in 2030 at a compound annual growth rate (CAGR) of 13% • Growth Driver: Erythropoietin Market Gains Momentum Amid Rising Incidence Of Chronic Kidney Diseases • Market Trend: Introduction Of Oral Medications To Enhance Convenience • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Erythropoietin (EPO) Market?

Erythropoietin (EPO) refers to a glycoprotein hormone that naturally induces the generation of red blood cells and is produced by the kidney's peritubular cells. Red blood cell scarcity, or anemia, is treated with it. Weakness, weariness, and shortness of breath are signs of anemia because red blood cells deliver oxygen to the tissues and organs. The main types of products in erythropoietin are epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. Epoetin alfa is a recombinant DNA-derived human erythropoietin generated in cell culture. The different drug classes include biologics, and biosimilar and are used in cancer, hematology, renal diseases, neurology, and others.

What Is The Erythropoietin (EPO) Market Growth Forecast?

The erythropoietin (epo) market size is expected to see rapid growth in the next few years. It will grow to $35.04 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to expanding biosimilar approvals, increasing elderly population base, rising global dialysis patient volume, innovation in sustained release epo drugs, improving access to biologic therapies in emerging economies. Major trends in the forecast period include expanded use of erythropoietin in chronic kidney disease, rising adoption of biosimilar erythropoietin therapies, growing demand for long acting epo formulations, increasing use of epo in oncology supportive care, stricter regulatory oversight on epo safety and dosing.

Global Erythropoietin (EPO) Market Segmentation

1) By Product: Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Other Products 2) By Drug Class: Biologist, Biosimilar 3) By Application: Cancer, Hematology, Renal Diseases, Neurology, Other Applications Subsegments: 1) By Epoetin-Alfa: Epoetin-Alfa, Epoetin-Alfa Biosimilars 2) By Epoetin-Beta: Epoetin-Beta, Epoetin-Beta Biosimilars 3) By Darbepoetin-Alfa: Darbepoetin-Alfa, Darbepoetin-Alfa Biosimilars 4) By Other Products: Peginesatide, Novel EPO Products

What Are The Drivers Of The Erythropoietin (EPO) Market?

The rising incidence of chronic kidney diseases is anticipated to propel the demand for the erythropoietin market over the coming years. The growing cases of chronic kidney disease require erythropoietin administration, which is used to make red blood cells to improve immunity. For instance, in 2023, according to the Centers for Disease Control, a US-based federal agency, approximately 14% of U.S. adults, equating to around 35.5 million people, are estimated to have chronic kidney disease (CKD). Therefore, the rising incidence of chronic kidney diseases increases the demand for erythropoietin, thereby driving the market revenues. The increasing incidence of hematologic cancer is expected to drive the growth of the erythropoietin market going forward. Hematologic cancer refers to a group of cancers that originate in the blood and affect the blood, bone marrow, and lymphatic system and includes diseases such as leukemia, lymphoma, and myeloma. Erythropoietin (EPO) plays a significant role in managing cancer-related anemia. It stimulates the production of red blood cells, helping alleviate anemia in cancer patients, particularly those undergoing chemotherapy. For instance, in 2023, according to the American Cancer Society, a US-based voluntary health organization focusing on eliminating cancer, leukemia is estimated to affect 59,610 American and cause 23,710 deaths. Furthermore, new patients of non-Hodgkin lymphoma are expected to affect 80,550 people in the United States and cause 20,180 deaths. Thus, the increasing prevalence of hematologic cancers is propelling the erythropoietin market forward.

Key Players In The Global Erythropoietin (EPO) Market

Major companies operating in the erythropoietin (epo) market are Amgen Inc., Roche Holding AG, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Ltd., 3SBio Inc., Celltrion Inc., Intas Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Reliance Life Sciences Pvt. Ltd., Biocon Limited, Chugai Pharmaceutical Co., Kyowa Kirin Co. Ltd., Apotex Inc., CJ Healthcare Corp., STADA Arzneimittel AG, Hospira Inc., Sandoz International GmbH, Torrent Pharmaceuticals Ltd., LG Life Sciences Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals.

Global Erythropoietin (EPO) Market Trends and Insights

Major companies in the erythropoietin market are focusing on the introduction of oral medications that offer more convenient alternatives to traditional injectable therapies. This aims to improve patient comfort, compliance, and treatment flexibility, particularly for individuals managing chronic conditions like anemia in chronic kidney disease (CKD). For instance, in February 2023, GlaxoSmithKline (GSK), a UK-based multinational pharmaceutical and biotechnology company, launched Jesduvroq (daprodustat) tablets. This oral medication helps boost erythropoietin levels helping to manage anemia in CKD patients by keeping hemoglobin levels within a target range. The key aim of Jesduvroq is to provide a more convenient alternative to injectable therapies, improving patient comfort, compliance, and treatment flexibility for dialysis patients.

Regional Insights

North America was the largest region in the erythropoietin (EPO) market in 2025. The Middle East is expected to be the fastest growing region in the global erythropoietin (EPO) market analysis in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Erythropoietin (EPO) Market?

The erythropoietin market consists of sales of epoetin, darbepoetin, and methoxy polyethylene glycol-epoetin beta. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Erythropoietin (EPO) Market Report 2026?

The erythropoietin (epo) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the erythropoietin (epo) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.